Literature DB >> 29790084

Cloning and expression of nlpA gene as DNA vaccine candidate against Acinetobacter baumannii.

Rassoul Hashemzehi1,2, Abbas Doosti3, Mohammad Kargar4, Mojtaba Jaafarinia2.   

Abstract

Acinetobacter baumannii is one of the highly antibiotic-resistant bacteria that cause infections with high rate of death. This bacterium is one the common causes of infection worldwide leading to endemic and epidemic nosocomial infections. Despite many efforts, there is no effective vaccine against A. baumannii. As NlpA is one of the important antigenic factors in biogenesis of outer membrane vesicles, and OMV-based reported vaccines in A. baumannii stimulated the immune responses, this study was aimed to clone and express nlpA gene in eukaryotic HDF cells and evaluate the induced immunization following the administration of resulting construct as DNA vaccine in BALB/c mice. The nlpA gene of A. baumannii was amplified using PCR. The PCR product was then cloned and subcloned into the pTZ57R/T and pEGFP-C2 vectors respectively. The cloning was confirmed by PCR, restriction enzyme digestion and DNA sequencing. The pEGFP-C2-nlpA recombinant plasmid was transferred into the HDF cells using electroporation and the expression of target gene was validated by RT-PCR. The recombinant construct was injected to BALB/c mice through three IM injections and the levels of IgG, IgM, INF-γ, IL-2, IL-4, and IL-12 were determined using ELISA assay. The A. baumannii nlpA gene was amplified during PCR as 867 bp band which was successfully cloned in pEGFP-C2-nlpA vector. Obtained data from RT-PCR and presence of the 867 bp fragment in transformed HDF cells confirmed the nlpA gene expression. Following the injection of pEGFP-C2-nlpA showed the increased level of IgG, IgM, INF-γ, IL-2, IL-4, and IL-12 in serum of immunized mice. Overall, through this study recombinant pEGFP-C2-nlpA was generated and successfully expressed the A. baumannii nlpA gene in eukaryotic cells. Additionally, our in vivo study confirmed that the recombinant construct capable to induce the immune response in immunized mice. These findings suggest the pEGFP-C2-nlpA may be considered as DNA vaccine candidate against A. baumannii.

Entities:  

Keywords:  Acinetobacter baumannii; DNA vaccine; Gene expression; Immunization; nlpA

Mesh:

Substances:

Year:  2018        PMID: 29790084     DOI: 10.1007/s11033-018-4167-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

1.  Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.

Authors:  Hadi Razavi Nikoo; Abdollah Ardebili; Jalal Mardaneh
Journal:  Microb Drug Resist       Date:  2017-01-13       Impact factor: 3.431

2.  Synthetic effect between envelope stress and lack of outer membrane vesicle production in Escherichia coli.

Authors:  Carmen Schwechheimer; Meta J Kuehn
Journal:  J Bacteriol       Date:  2013-07-12       Impact factor: 3.490

3.  Lipoprotein 28, an inner membrane protein of Escherichia coli encoded by nlpA, is not essential for growth.

Authors:  K Yamaguchi; M Inouye
Journal:  J Bacteriol       Date:  1988-08       Impact factor: 3.490

4.  Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii.

Authors:  Michael J McConnell; Carlos Rumbo; Germán Bou; Jerónimo Pachón
Journal:  Vaccine       Date:  2011-06-14       Impact factor: 3.641

5.  OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections.

Authors:  Weiwei Huang; Shijie Wang; Yufeng Yao; Ye Xia; Xu Yang; Qiong Long; Wenjia Sun; Cunbao Liu; Yang Li; Yanbing Ma
Journal:  Vaccine       Date:  2015-07-21       Impact factor: 3.641

6.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

7.  DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice.

Authors:  Qun Wang; Wei Cao; Zhi-Gang Yang; Guang-Fa Zhao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  In vivo validation of the immunogenicity of recombinant Baumannii Acinetobactin Utilization A protein (rBauA).

Authors:  Hamid Esmaeilkhani; Iraj Rasooli; Shahram Nazarian; Fatemeh Sefid
Journal:  Microb Pathog       Date:  2016-06-29       Impact factor: 3.738

9.  Antibiotic Resistance Determinant-Focused Acinetobacter baumannii Vaccine Designed Using Reverse Vaccinology.

Authors:  Zhaohui Ni; Yan Chen; Edison Ong; Yongqun He
Journal:  Int J Mol Sci       Date:  2017-02-21       Impact factor: 5.923

10.  Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis.

Authors:  Maryam Pourhajibagher; Farhad B Hashemi; Babak Pourakbari; Masoud Aziemzadeh; Abbas Bahador
Journal:  Open Microbiol J       Date:  2016-03-29
View more
  4 in total

1.  Decoding Acinetobacter baumannii biofilm dynamics and associated protein markers: proteomic and bioinformatics approach.

Authors:  Monika Choudhary; Shubham Kaushik; Arti Kapil; Rahul Shrivastava; Jitendraa Vashistt
Journal:  Arch Microbiol       Date:  2022-03-03       Impact factor: 2.552

2.  Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine.

Authors:  Mohammad Chehelgerdi; Abbas Doosti
Journal:  J Nanobiotechnology       Date:  2020-04-21       Impact factor: 10.435

Review 3.  Current trends in targeted therapy for drug-resistant infections.

Authors:  Leila Rahbarnia; Safar Farajnia; Behrooz Naghili; Vahideh Ahmadzadeh; Kamal Veisi; Roghayyeh Baghban; Sayna Toraby
Journal:  Appl Microbiol Biotechnol       Date:  2019-08-14       Impact factor: 4.813

Review 4.  Promising Acinetobacter baumannii Vaccine Candidates and Drug Targets in Recent Years.

Authors:  Yong Chiang Tan; Chandrajit Lahiri
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.